NZ757213A - Compositions of plinabulin and use thereof - Google Patents
Compositions of plinabulin and use thereofInfo
- Publication number
- NZ757213A NZ757213A NZ757213A NZ75721318A NZ757213A NZ 757213 A NZ757213 A NZ 757213A NZ 757213 A NZ757213 A NZ 757213A NZ 75721318 A NZ75721318 A NZ 75721318A NZ 757213 A NZ757213 A NZ 757213A
- Authority
- NZ
- New Zealand
- Prior art keywords
- combination
- plinabulin
- immune checkpoint
- compositions
- checkpoint inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762470802P | 2017-03-13 | 2017-03-13 | |
| US201862621528P | 2018-01-24 | 2018-01-24 | |
| PCT/US2018/022064 WO2018169887A1 (en) | 2017-03-13 | 2018-03-12 | Compositions of plinabulin and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ757213A true NZ757213A (en) | 2022-01-28 |
Family
ID=63522552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ757213A NZ757213A (en) | 2017-03-13 | 2018-03-12 | Compositions of plinabulin and use thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200129504A1 (enExample) |
| EP (2) | EP4190326A1 (enExample) |
| JP (3) | JP7280192B2 (enExample) |
| KR (1) | KR102659907B1 (enExample) |
| CN (1) | CN110603037A (enExample) |
| AU (2) | AU2018236168B2 (enExample) |
| BR (1) | BR112019018880A2 (enExample) |
| CA (1) | CA3056077A1 (enExample) |
| DK (1) | DK3595653T3 (enExample) |
| ES (1) | ES2942889T3 (enExample) |
| NZ (1) | NZ757213A (enExample) |
| SG (1) | SG11201908420WA (enExample) |
| WO (1) | WO2018169887A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6769982B2 (ja) | 2015-03-06 | 2020-10-14 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | Ｒａｓ変異と関連するがんの治療方法 |
| EP3265091A4 (en) | 2015-03-06 | 2018-08-01 | Beyondspring Pharmaceuticals Inc. | Method of treating a brain tumor |
| CN108026075B (zh) | 2015-07-13 | 2021-06-29 | 大连万春布林医药有限公司 | 普那布林组合物 |
| RU2753543C1 (ru) | 2016-02-08 | 2021-08-17 | Бейондспринг Фармасьютикалс, Инк. | Композиции, содержащие тукаресол или его аналоги |
| EP3463337A4 (en) | 2016-06-06 | 2020-02-12 | Beyondspring Pharmaceuticals, Inc. | COMPOSITION AND METHOD FOR REDUCING NEUTROPENIA |
| WO2018129381A1 (en) | 2017-01-06 | 2018-07-12 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| SG11201907023UA (en) | 2017-02-01 | 2019-08-27 | Beyondspring Pharmaceuticals Inc | Method of reducing neutropenia |
| GB201713760D0 (en) * | 2017-08-28 | 2017-10-11 | Univ Leuven Kath | Treatment of epilepsy |
| BR112020014960A2 (pt) | 2018-01-24 | 2020-12-22 | Beyondspring Pharmaceuticals, Inc. | Composição e método para redução de trombocitopenia |
| WO2019232257A1 (en) * | 2018-06-01 | 2019-12-05 | Beyondspring Pharmaceuticals, Inc. | Composition and method of treating cancer associated with egfr mutation |
| GB201913988D0 (en) | 2019-09-27 | 2019-11-13 | Celleron Therapeutics Ltd | Novel treatment |
| CN113613654B (zh) * | 2019-10-15 | 2024-01-26 | 大连万春布林医药有限公司 | 普那布林在制备增加非转移性乳腺癌患者触珠蛋白的药物中的用途 |
| US20230181605A1 (en) * | 2020-05-04 | 2023-06-15 | Beyondspring Pharmaceuticals, Inc. | Triple combination therapy for enhancing cancer cell killing in cancers with low immunogenicity |
| KR102428863B1 (ko) * | 2020-08-11 | 2022-08-03 | 서울대학교병원 | 자가면역 뇌염 발생 가능성 예측을 위한 정보 제공 방법 |
| WO2022133492A1 (en) * | 2020-12-18 | 2022-06-23 | Beyondspring Pharmaceuticals, Inc. | Compositions and methods for generating anti-tumor immune response |
| JP2024513505A (ja) | 2021-04-09 | 2024-03-25 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 腫瘍を治療するための組成物及び方法 |
| CN113456643B (zh) * | 2021-08-11 | 2022-04-01 | 遵义医科大学 | 一种含普那布林的药物组合及其应用 |
| WO2023154755A1 (en) * | 2022-02-10 | 2023-08-17 | Beyondspring Pharmaceuticals, Inc. | Stable plinabulin formulations and methods of their preparation and use |
| CN117860672A (zh) | 2022-10-11 | 2024-04-12 | 大连万春布林医药有限公司 | 一种普那布林胶束组合物及其制备方法 |
| WO2025006507A1 (en) * | 2023-06-27 | 2025-01-02 | Beyondspring Pharmaceuticals, Inc. | Oncology combination therapy and methods of use |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| US4919934A (en) | 1989-03-02 | 1990-04-24 | Richardson-Vicks Inc. | Cosmetic sticks |
| US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
| EP1392262A1 (en) | 2001-05-24 | 2004-03-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
| US7935704B2 (en) * | 2003-08-01 | 2011-05-03 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| US7919497B2 (en) * | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| ATE374767T1 (de) * | 2002-08-02 | 2007-10-15 | Nereus Pharmaceuticals Inc | Dehydrophenylahistine und analoge davon sowie ein verfahren zur herstellung von dehydrophenylahistinen und analogen davon |
| AU2005212399B2 (en) * | 2004-02-04 | 2011-09-22 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| TW200711649A (en) * | 2005-06-17 | 2007-04-01 | Combinatorx Inc | Combination therapy for the treatment of immunoinflammatory disorders |
| EP1926724A1 (en) * | 2005-09-21 | 2008-06-04 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| WO2012035436A1 (en) * | 2010-09-15 | 2012-03-22 | Tokyo University Of Pharmacy And Life Sciences | Plinabulin prodrug analogs and therapeutic uses thereof |
| JP6311097B2 (ja) * | 2013-07-31 | 2018-04-18 | 学校法人東京薬科大学 | 微小管脱重合剤 |
| KR102225371B1 (ko) * | 2013-10-11 | 2021-03-10 | 비욘드스프링인크. | 플리나불린 및 탁산의 조합에 의한 암 치료 |
| NZ734256A (en) * | 2015-02-12 | 2019-02-22 | Beyondspring Pharmaceuticals Inc | Use of plinabulin in combination with immune checkpoint inhibitors |
| RU2753543C1 (ru) * | 2016-02-08 | 2021-08-17 | Бейондспринг Фармасьютикалс, Инк. | Композиции, содержащие тукаресол или его аналоги |
-
2018
- 2018-03-12 DK DK18768238.0T patent/DK3595653T3/da active
- 2018-03-12 KR KR1020197029387A patent/KR102659907B1/ko active Active
- 2018-03-12 NZ NZ757213A patent/NZ757213A/en unknown
- 2018-03-12 EP EP23153650.9A patent/EP4190326A1/en not_active Withdrawn
- 2018-03-12 AU AU2018236168A patent/AU2018236168B2/en active Active
- 2018-03-12 ES ES18768238T patent/ES2942889T3/es active Active
- 2018-03-12 WO PCT/US2018/022064 patent/WO2018169887A1/en not_active Ceased
- 2018-03-12 CA CA3056077A patent/CA3056077A1/en active Pending
- 2018-03-12 EP EP18768238.0A patent/EP3595653B1/en active Active
- 2018-03-12 US US16/493,271 patent/US20200129504A1/en not_active Abandoned
- 2018-03-12 CN CN201880029191.0A patent/CN110603037A/zh active Pending
- 2018-03-12 JP JP2019550138A patent/JP7280192B2/ja active Active
- 2018-03-12 BR BR112019018880A patent/BR112019018880A2/pt active Search and Examination
- 2018-03-12 SG SG11201908420W patent/SG11201908420WA/en unknown
-
2023
- 2023-05-11 JP JP2023078735A patent/JP2023099217A/ja active Pending
-
2024
- 2024-02-06 AU AU2024200709A patent/AU2024200709A1/en not_active Abandoned
-
2025
- 2025-07-04 JP JP2025113816A patent/JP2025138849A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3595653A1 (en) | 2020-01-22 |
| US20200129504A1 (en) | 2020-04-30 |
| AU2018236168B2 (en) | 2024-02-29 |
| ES2942889T3 (es) | 2023-06-07 |
| EP3595653B1 (en) | 2023-03-08 |
| JP2025138849A (ja) | 2025-09-25 |
| JP7280192B2 (ja) | 2023-05-23 |
| CA3056077A1 (en) | 2018-09-20 |
| KR20190122822A (ko) | 2019-10-30 |
| AU2018236168A1 (en) | 2019-10-10 |
| SG11201908420WA (en) | 2019-10-30 |
| WO2018169887A1 (en) | 2018-09-20 |
| DK3595653T3 (da) | 2023-04-17 |
| CN110603037A (zh) | 2019-12-20 |
| BR112019018880A2 (pt) | 2020-04-14 |
| EP4190326A1 (en) | 2023-06-07 |
| JP2023099217A (ja) | 2023-07-11 |
| JP2020520889A (ja) | 2020-07-16 |
| KR102659907B1 (ko) | 2024-04-24 |
| EP3595653A4 (en) | 2020-11-11 |
| AU2024200709A1 (en) | 2024-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ757213A (en) | Compositions of plinabulin and use thereof | |
| ZA202007007B (en) | Mcl-1 inhibitors | |
| PH12020550857A1 (en) | Polycyclic compounds as allosteric shp2 inhibitors | |
| MX2022007472A (es) | Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario. | |
| PH12019502132A1 (en) | Combination therapy for the treatment or prevention of tumours | |
| MX2023004037A (es) | Compuestos biciclicos como inhibidores alostericos de shp2. | |
| MX2019008696A (es) | Compuestos de piridina como inhibidores de shp2 alostericos. | |
| ZA201903327B (en) | Compositions and methods for the induction of cd8+ t¿cells | |
| PH12019501763A1 (en) | Method of reducing neutropenia | |
| MX370624B (es) | Composiciones que incluyen extractos de ampelopsis grossedentata y albizia julibrissin y métodos para uso. | |
| MX2017014253A (es) | Metodos y composiciones para promover el crecimiento del cabello. | |
| MX2017003227A (es) | Terapias de combinacion de inhibidores de alk. | |
| MX2015016100A (es) | Inhibidores de criopirina para prevenir y tratar la inflamacion. | |
| EA202090632A1 (ru) | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов | |
| MX2019009122A (es) | ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTOEGENESIS IMPERFECTA (OI). | |
| MX386613B (es) | El uso de un péptido timosina alfa y un inhibidor de pd-1 para el tratamiento de cáncer o una metástasis de este en un sujeto. | |
| PH12019502049A1 (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| MX2018004132A (es) | Método de tratamiento de meduloblastoma con un inhibidor de ezh2. | |
| MX2021013354A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| MX2018005825A (es) | Celulas inmunes modificadas y usos de las mismas. | |
| MX383944B (es) | Composiciones para el cuidado personal. | |
| SA519410324B1 (ar) | صياغات رش إيبينيفرين | |
| PH12017501980A1 (en) | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc) | |
| MX374385B (es) | Apilimod para uso en el tratamiento de melanoma. | |
| MX2020002585A (es) | Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAR 2024 BY CPA GLOBAL Effective date: 20230127 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240125 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 MAR 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20250123 |